Acute Management of Pediatric Asthma Exacerbation

1. Immediate Assessment and Red‑Flag Identification

Worsening symptoms after starting an inhaler often indicate improper inhaler technique or use of an unsuitable device in children, who typically cannot coordinate an unmodified metered‑dose inhaler (MDI) [1][2].
Periorbital redness or swelling is not a typical feature of asthma and should prompt evaluation for alternative diagnoses such as sinusitis, allergic reaction, or orbital cellulitis [3][4].

Children around 11 years old should use an MDI with a large‑volume spacer (preferred over nebulizer) or a dry‑powder inhaler if they can demonstrate adequate technique [1][2][5].
Nebulizers are frequently overused in this age group and should be replaced by spacer devices in most cases [1][2][5].
Failure to assess and correct inhaler technique is the most common reason for treatment failure in pediatric asthma [1][2][5].

Administer short‑acting β₂‑agonist (salbutamol) promptly, either via nebulizer (2.5–5 mg) or via MDI with spacer (100 µg per actuation, up to 20 actuations) [1][2].
Re‑evaluate clinical response (respiratory rate, heart rate, work of breathing, wheeze) after 15–30 minutes [1][2].

Oral prednisolone 1–2 mg/kg once daily (maximum 40 mg) should be started without delay in children with severe symptoms [1][2].
A short course of 3–5 days is recommended [1][2].

If no improvement after the initial bronchodilator dose, add ipratropium bromide 250 µg to the nebulizer, repeating every 6 hours [1][2].

Obtain a chest radiograph immediately to exclude pneumonia, foreign body aspiration, or structural abnormalities [3][6].
Perform spirometry with pre‑ and post‑bronchodilator measurements to confirm reversible airway obstruction [3][6].
Normal vital signs do not rule out serious pathology; systematic evaluation remains essential [3][4].
Consider targeted testing based on clinical clues:
- Pertussis PCR or culture if paroxysmal cough with post‑tussive vomiting [6].
- Airway hyper‑responsiveness testing if spirometry is inconclusive [6].
- Tuberculosis testing when exposure history is present [6].

Treatment should be etiology‑driven; empirical simultaneous therapy for upper‑airway cough syndrome, GERD, and asthma is discouraged unless specific features are identified [7].
When an empirical trial is used, limit it to 2–4 weeks with reassessment to confirm or refute the diagnosis [7].

For confirmed asthma in atopic children, start low‑dose ICS (≈ 400 µg/day beclomethasone‑equivalent) as the main preventive therapy [1][8].
All children using an MDI for ICS must employ a large‑volume spacer to improve lung deposition [1][2][5].
Reassess response after 2–4 weeks; discontinue if no clinical benefit and reconsider the diagnosis [4][7].

If clinical improvement occurs:
- Continue salbutamol every 4 hours, complete the prednisolone course, and arrange home management with close follow‑up within one week [1][2].
- Provide a written asthma action plan and verify correct inhaler technique before discharge [1][2].
If no improvement or deterioration:
- Admit to hospital promptly, increase bronchodilator frequency to every 30 minutes, maintain oxygen and systemic steroids, and investigate alternative diagnoses such as foreign‑body aspiration or pneumonia [1][4][7].

Aim for minimal daytime symptoms, no nocturnal awakenings, full participation in activities, and infrequent reliever use [1][5].
Maintain low‑dose inhaled corticosteroids as the cornerstone of persistent asthma management [1][8].
Address environmental triggers, especially exposure to tobacco smoke [4].
Provide a peak‑flow meter for home monitoring of lung function [1].

Initiate low‑dose inhaled corticosteroids (≤ 400 µg/day beclomethasone‑equivalent) as the primary preventive treatment for children with confirmed asthma, offering effective control with minimal side‑effects and convenient twice‑daily dosing. 9
Require the use of a large‑volume spacer with any metered‑dose inhaler delivering inhaled steroids to improve lung deposition and reduce systemic absorption. 9
No convincing evidence demonstrates clinically important differences among the currently available inhaled‑steroid formulations; therefore, prescribe the lowest dose that achieves acceptable asthma control. 9

Aim for minimal daytime symptoms, absence of nocturnal awakenings, unrestricted participation in school and sports, and infrequent use of reliever medication. 9
Short‑term use of inhaled steroids at doses > 400 µg/day may transiently reduce tibial growth rate, but these findings cannot be extrapolated to long‑term growth outcomes. 9

Provide both oral and written instructions that cover correct inhaler technique, warning signs that require urgent medical attention, and strategies for avoiding environmental asthma triggers. 9
Educate caregivers on the distinction between “relievers” (short‑acting bronchodilators such as salbutamol) and “preventers” (anti‑inflammatory agents such as inhaled corticosteroids). 9
Supply a peak‑flow meter for home use and incorporate regular monitoring of symptoms, peak‑flow values, and medication usage into a personalized written asthma action plan. 9